M
7.51
0.59 (8.53%)
| Previous Close | 6.92 |
| Open | 6.99 |
| Volume | 448,022 |
| Avg. Volume (3M) | 546,280 |
| Market Cap | 603,544,192 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 16.01 |
| Price / Book | 18.23 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | MeiraGTx Holdings plc | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.38 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Knoll Capital Management, Llc | 31 Mar 2025 | 1,250,000 |
| 52 Weeks Range | ||
| Median | 35.00 (366.05%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 14 May 2025 | 35.00 (366.05%) | Buy | 4.64 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | MeiraGTx Reports First Quarter 2025 Financial and Operational Results |
| 13 May 2025 | Announcement | MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting |
| 09 May 2025 | Announcement | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |